Lilly Is Attentive To ADHD: Tomoxetine Into Phase III; 2001 NDA Planned
Executive Summary
Tomoxetine for attention deficit hyperactivity disorder could be the next neuroscience entry from Lilly, building on the Prozac and Zyprexa franchises.
You may also be interested in...
Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients
Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.
Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients
Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.
FDA's Proposed Osteoporosis Definition For PTH Trials Questioned By Lilly
FDA's proposed limitations on clinical trial eligibility for parathyroid hormone osteoporosis studies are too restrictive, Lilly said in Aug. 4 comments on FDA's "Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis" draft guidance.